Is Mounjaro Available in Ireland – 2025 Status, Prices and Access Guide

Mounjaro (tirzepatide), the dual-glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly, has become increasingly relevant for patients in Ireland seeking treatment for type 2 diabetes and weight management. The medication received Health Products Regulatory Authority (HPRA) authorisation on April 19, 2024, establishing a formal pathway for Irish patients to access this treatment through private prescription. Understanding the current availability status, regulatory framework, access routes, and costs associated with Mounjaro in Ireland requires careful navigation of the healthcare system.

Is Mounjaro Available in Ireland?

Mounjaro became legally available for private prescription in Ireland in February 2025, representing a significant milestone for patients seeking this medication. The drug is classified as a prescription-only medication, meaning it cannot be purchased over the counter and requires consultation with a qualified Irish doctor. The European Medicines Agency (EMA) had previously determined that Mounjaro’s benefits outweigh its risks for use within the European Union, providing the foundation for national regulatory approval.

While Mounjaro is licensed specifically for type 2 diabetes treatment, it is being prescribed off-label by Irish doctors for weight management purposes. This off-label prescribing remains at the professional discretion of individual physicians, who must assess each patient’s eligibility and medical circumstances before issuing a prescription.

Understanding Irish Availability Status

The availability of Mounjaro in Ireland operates through a private healthcare model. Patients seeking access must arrange consultations with private doctors who can evaluate their suitability for the medication. Unlike some other countries where weight-loss medications have been available through expanded channels, Ireland maintains a strictly prescription-based approach for Mounjaro.

Supply routes include both Irish private pharmacies and Northern Irish pharmacies, with the latter often offering more competitive pricing and direct delivery to Republic of Ireland addresses. This cross-border availability reflects the interconnected nature of pharmaceutical supply chains on the island of Ireland, though patients should ensure any pharmacy they use is appropriately licensed.

Are There Mounjaro Shortages in Ireland?

The research materials do not provide specific information regarding current supply shortages affecting Mounjaro in Ireland. Patients interested in accessing the medication should consult directly with pharmacies regarding stock availability, as pharmaceutical supplies can fluctuate based on demand and distribution factors. The medication’s relatively recent introduction to the Irish market in February 2025 means supply chains may still be establishing themselves.

Mounjaro Approval Status in Ireland

The regulatory pathway for Mounjaro in Ireland involved careful evaluation by both European and national authorities. The European Medicines Agency conducted a comprehensive assessment concluding that the benefits of tirzepatide outweigh its risks, which enabled subsequent national authorisation processes across EU member states including Ireland.

Is Mounjaro Approved by HPRA?

Yes, Mounjaro received formal HPRA authorisation on 19 April 2024 as a prescription-only medication. The Health Products Regulatory Authority is Ireland’s competent authority for regulating medicines, and this authorisation confirms that the medication has met the required standards for safety, efficacy, and quality for the specified indication of type 2 diabetes treatment.

The HPRA authorisation specifically covers the use of Mounjaro for type 2 diabetes management. For weight management applications, prescribing occurs off-label, which means doctors take direct professional responsibility for assessing individual patient circumstances and determining appropriate treatment protocols outside the formally approved indication.

Where and How to Get Mounjaro in Ireland

Accessing Mounjaro in Ireland requires navigating the private healthcare system, as the medication is not currently covered by the Health Service Executive (HSE) for either diabetes or obesity treatment. Patients must obtain a private prescription from an Irish doctor and pay for the medication out of pocket.

Where Can I Buy Mounjaro in Ireland?

Mounjaro can be obtained from Irish private pharmacies and Northern Irish pharmacies following a valid private prescription. Several specialised weight-loss and diabetes pharmacies have emerged to serve patients seeking this medication, with some Northern Irish providers offering direct delivery to Republic of Ireland addresses.

When purchasing from any pharmacy, patients should verify that the establishment is properly licensed and authorised to dispense prescription medications. Both the Irish and Northern Irish pharmacy regulators maintain registers that allow patients to confirm the legitimacy of their chosen supplier.

How to Get a Mounjaro Prescription in Ireland

Obtaining a Mounjaro prescription in Ireland involves scheduling a private consultation with a doctor who is willing to prescribe the medication. During this consultation, the physician will evaluate whether the patient meets the clinical criteria for treatment, which typically includes assessment of body mass index and any existing weight-related health conditions.

Typical Eligibility Criteria

Irish doctors typically consider prescribing Mounjaro to patients who meet certain clinical thresholds:

• Body mass index (BMI) of 30 or higher, which classifies as obese under standard medical definitions
• BMI of 27 or higher combined with at least one weight-related health condition such as high blood pressure, obstructive sleep apnoea, type 2 diabetes, or cardiovascular disease

These criteria align with clinical guidelines for GLP-1 receptor agonist treatments and reflect the medication’s evidence base from clinical trials. The final prescribing decision rests with the individual doctor, who must be satisfied that treatment is appropriate for the specific patient’s circumstances.

Can I Buy Mounjaro Online in Ireland?

Patients can purchase Mounjaro through online pharmacies following receipt of a valid private prescription. However, any online pharmacy used should be appropriately licensed and authorised to dispense prescription medications in Ireland or Northern Ireland. Patients should exercise caution regarding unfamiliar websites offering medications without requiring prescriptions, as these may be operating illegally or supplying counterfeit products.

Legitimate online pharmacies will require submission of a valid prescription before dispensing Mounjaro. The medication’s status as a prescription-only product means any supplier offering it without prescription requirements should be approached with significant caution.

Mounjaro Pricing and Coverage in Ireland

The cost of Mounjaro treatment represents a significant consideration for Irish patients, as the medication is not subsidised through the public healthcare system. Pricing varies based on the specific dose prescribed and the pharmacy from which the medication is purchased.

What is the Price of Mounjaro in Ireland?

Mounjaro pricing in Ireland reflects the private prescription model through which the medication is accessed:

• Per pen pricing: Ranges from £169 to £319 depending on the dose strength prescribed
• Monthly treatment cost: Typically exceeds €215 for private prescriptions
• Doses per pen: Each pen contains four weekly doses of the medication

The variation in pricing between different pharmacies can be substantial, with Northern Irish pharmacies frequently offering more competitive rates than Irish-based providers. Patients may wish to compare pricing across multiple authorised suppliers before committing to a purchase, though they should ensure the pharmacy is properly licensed regardless of price considerations.

Is Mounjaro Covered by HSE in Ireland?

Mounjaro is not currently covered by the HSE for obesity treatment, and the medication remains outside the public reimbursement framework. However, the process for potential future coverage is actively underway.

Eli Lilly, the manufacturer of Mounjaro, submitted applications to the HSE for reimbursement consideration in two stages: For those interested in currency conversions, you can find more information about 110 pounds to euro at 110 pounds to euro.

• January 2024: Application submitted for type 2 diabetes indication
• June 2024: Application submitted for obesity treatment indication

The National Centre for Pharmacoeconomics (NCPE) reviewed these applications and recommended that a full health technology assessment be conducted for both indications. This assessment process involves detailed evaluation of clinical effectiveness, cost-effectiveness, and budget impact.

HSE Reimbursement Timeline

Health Minister Jennifer Carroll MacNeill indicated that an outcome from the HSE reimbursement process could be expected by the fourth quarter of 2025 or the first quarter of 2026. However, the NCPE assessment concluded that the multi-billion euro cost of providing Mounjaro to all eligible patients was not considered value for money despite the medication’s demonstrated effectiveness in clinical trials.

Eli Lilly has stated it would “work with the HSE to explore solutions that enable patient access in Ireland” as the reimbursement process continues. This suggests ongoing negotiations may lead to more limited reimbursement schemes or managed access programmes in the future.

Key Developments Timeline

The following timeline outlines the major regulatory and access milestones for Mounjaro in Ireland:

1. 2022: European Medicines Agency determines Mounjaro benefits outweigh risks for EU use
2. January 2024: Eli Lilly submits HSE reimbursement application for type 2 diabetes indication
3. April 2024: Health Products Regulatory Authority grants formal authorisation for Mounjaro
4. June 2024: Eli Lilly submits HSE reimbursement application for obesity treatment
5. NCPE Assessment: National Centre for Pharmacoeconomics recommends full health technology assessment
6. February 2025: Mounjaro becomes legally available through private prescription in Ireland
7. Anticipated Q4 2025/Q1 2026: Potential HSE reimbursement decision expected

Clinical Efficacy and Treatment Considerations

Clinical trials have demonstrated that Mounjaro produces significant weight loss outcomes for patients using the medication as directed. Studies indicate that patients using Mounjaro can expect to lose between 15% and 20% of their body weight over a treatment period of approximately one year when combined with appropriate lifestyle modifications.

The medication’s dual-hormone action mechanism, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, distinguishes it from older GLP-1 receptor agonist medications such as Ozempic. This dual action is considered to contribute to the medication’s superior efficacy profile in clinical trials.

Alternatives to Mounjaro in Ireland

For patients unable to access Mounjaro, whether due to cost, availability, or clinical contraindications, alternative treatment options exist within the Irish healthcare system. Saxenda represents the currently available weight-loss injection that has received some public funding support.

HSE-Funded Alternatives

Saxenda (liraglutide) is currently the only weight-loss injection that has achieved funding through the HSE scheme. Access to funded Saxenda treatment is available to adult patients meeting specific clinical criteria:

• Adult patients with prediabetes
• Patients at high risk of cardiovascular disease
• Those meeting certain BMI requirements as assessed by their healthcare provider

Unlike Mounjaro, which operates through a private prescription model with no HSE support, Saxenda has an established pathway for patients to access the medication through the public healthcare system if they satisfy the eligibility criteria.

Reporting Adverse Effects

Patients experiencing side effects or adverse reactions while using Mounjaro should report these to their prescribing doctor or dispensing pharmacist. Additionally, the Health Products Regulatory Authority maintains a pharmacovigilance system where patients and healthcare professionals can directly report suspected adverse effects through the HPRA’s reporting platform.

The HPRA encourages reporting of all suspected adverse effects, even those that might be expected or commonly occurring, as this information contributes to the ongoing safety monitoring of medications authorised for use in Ireland.

Summary

Mounjaro (tirzepatide) is available in Ireland through private prescription following HPRA authorisation in April 2024 and market launch in February 2025. Patients seeking access must obtain prescriptions through private consultations with Irish doctors, with typical eligibility based on BMI thresholds and the presence of weight-related health conditions. The medication is not currently covered by the HSE, with patients paying between £169 and £319 per pen depending on dose strength, resulting in monthly costs exceeding €215.

The ongoing HSE reimbursement process may lead to future public coverage, with a decision anticipated by late 2025 or early 2026. Until such time, access remains through the private healthcare system with patients bearing the full cost of treatment. Saxenda represents the only currently HSE-funded weight-loss injection alternative for eligible patients.

Frequently Asked Questions